Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Nephrology | Oncology | Family Medicine
Search Medical Condition
Renal Cell Carcinoma Clinical Trials
A listing of Renal Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (293) clinical trials
Advanced Renal Cell Carcinoma
People with Renal Cell Carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.
People with Renal Cell Carcinoma are asked to participate in an immunotherapy research study being conducted by Montefiore Medical Center.
People with Renal Cell Carcinoma are asked to participate in an immunotherapy research study being conducted by Montefiore Medical Center.
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma
The primary objective of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review [IIR] using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]) as first-line ...
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)
Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to ...
A Phase IIb, Nonrandomized, Open-Label Trial with Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared with Best Supportive Care in Patients with Treatment-Resistant, Metastatic Colorectal Carcinoma
This phase II study is evaluating the safety (health risks and side effects) and efficacy of The Rogosin Institute’s investigational [not approved by the Food and Drug Administration (FDA)] macrobeads. The macrobeads are small-sugarcoated beads containing cancer cells from a mouse kidney cancer cell line and are surgically implanted in ...
Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01835158?term=A031203&rank=1
Advanced or Metastatic Renal Cell Carcinoma (RCC)
Advanced or Metastatic Renal Cell Carcinoma (RCC)
Metastatic Renal Cell Carcinoma
People with renal cell carcinoma are asked to participate in a research study being conducted by North Shore University Hospital.
